“There myelofibrosis it is a chronic disease which, in its full-blown stages, gradually worsens over the years, progressively compromising the general health conditions. In the most advanced cases, the disorders are debilitating and considerably affect daily life. The disease can make everyday activities that are usually done without difficulty, such as walking, climbing stairs, tidying up the house, showering, and cooking, very difficult. Many patients lose weight and lose muscle tone ”. Thus Antonella Barone, president of Aipamm – Odv (Italian Association of Patients with Diseases myeloproliferative) speaking this morning at the press conference dedicated to new opportunities in the treatment of myelofibrosis, an event organized in Rome and promoted by Celgene, now part of Bristol Myers Squibb.
“Woe to neglect the typical symptoms of hematological tumors – warns Barone -. For example, night sweats are a disabling disorder, because they prevent sleep and adequate rest, with serious repercussions also on emotional and family life. Furthermore, a person who gets tired easily tends to isolate himself, not to lead a social life with the risk of anxiety or depression. Patients experience a strong condition of uncertainty about the course and possible progression of the disease. With the drug fedratinib we have concrete hope that helps us to face the future with more confidence ”.
The availability “of a new therapeutic option in the myelofibrosis, proves that research is progressing, even in rare diseases. This is why it is essential to build bridges to foster collaboration between industry, institutions, haematologists and patient associations “, he concludes.
#Barone #Aipamm #Myelofibrosis #disabling #impact #patients #lives